Perrigo Company plc Segment Expenditure Addition To Long Lived Assets
Perrigo Company plc (PRGO) reported Segment Expenditure Addition To Long Lived Assets of $93.40 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Segment Reporting
us-gaap:SegmentExpenditureAdditionToLongLivedAssets · last filed 2026-02-26
- Perrigo Company plc segment expenditure addition to long lived assets for the quarter ending 2025-12-31 was $26.80M, a 28.91% decline year-over-year.
- Perrigo Company plc segment expenditure addition to long lived assets for the quarter ending 2025-09-27 was $21.90M, a 19.19% decline year-over-year.
- Perrigo Company plc segment expenditure addition to long lived assets for the quarter ending 2025-06-28 was $19.20M, a 32.39% decline year-over-year.
- Perrigo Company plc segment expenditure addition to long lived assets for the quarter ending 2025-03-29 was $25.50M, a 1.59% increase year-over-year.
- Perrigo Company plc segment expenditure addition to long lived assets for fiscal 2025 was $93.40M, a 21.05% decline from fiscal 2024.
- Perrigo Company plc segment expenditure addition to long lived assets for fiscal 2024 was $118.30M, a 16.32% increase from fiscal 2023.
- Perrigo Company plc segment expenditure addition to long lived assets for fiscal 2023 was $101.70M, a 7.85% increase from fiscal 2022.
- Perrigo Company plc segment expenditure addition to long lived assets for fiscal 2022 was $94.30M, a 30.66% decline from fiscal 2021.
| Period end | Segment Expenditure Addition To Long Lived Assets 3 month | Segment Expenditure Addition To Long Lived Assets 6 month | Segment Expenditure Addition To Long Lived Assets 9 month | Segment Expenditure Addition To Long Lived Assets 12 month |
|---|---|---|---|---|
| 2025-12-31 | $26.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $48.70M derived: sum of 2 quarters · filed 2026-02-26 | $67.90M derived: sum of 3 quarters · filed 2026-02-26 | $93.40M 10-K · filed 2026-02-26 |
| 2025-09-27 | $21.90M 10-Q · filed 2025-11-05 | $41.10M derived: sum of 2 quarters · filed 2025-11-05 | $66.60M 10-Q · filed 2025-11-05 | $104.30M derived: sum of 4 quarters · filed 2026-02-26 |
| 2025-06-28 | $19.20M 10-Q · filed 2025-08-06 | $44.70M 10-Q · filed 2025-08-06 | $82.40M derived: sum of 3 quarters · filed 2026-02-26 | $109.50M derived: sum of 4 quarters · filed 2026-02-26 |
| 2025-03-29 | $25.50M 10-Q · filed 2025-05-07 | $63.20M derived: sum of 2 quarters · filed 2026-02-26 | $90.30M derived: sum of 3 quarters · filed 2026-02-26 | $118.70M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-12-31 | $37.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $64.80M derived: sum of 2 quarters · filed 2026-02-26 | $93.20M derived: sum of 3 quarters · filed 2026-02-26 | $118.30M 10-K · filed 2026-02-26 |
| 2024-09-28 | $27.10M 10-Q · filed 2025-11-05 | $55.50M derived: sum of 2 quarters · filed 2025-11-05 | $80.60M 10-Q · filed 2025-11-05 | |
| 2024-06-29 | $28.40M 10-Q · filed 2025-08-06 | $53.50M 10-Q · filed 2025-08-06 | ||
| 2024-03-30 | $25.10M 10-Q · filed 2025-05-07 | |||
| 2023-12-31 | $101.70M 10-K · filed 2026-02-26 | |||
| 2022-12-31 | $94.30M 10-K · filed 2025-02-28 | |||
| 2021-12-31 | $136.00M 10-K · filed 2024-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |